Scilex Holding (SCLX) Operating Expenses (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Operating Expenses of $40.8 million for Q1 2026, up 23.95% year-over-year from $32.9 million in Q1 2025, and down 64.81% on a QoQ basis from $115.9 million in Q4 2025.
Scilex Holding (SCLX) Operating Expenses (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Operating Expenses for 7 consecutive years, with $40.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 23.95% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $384.1 million (up 169.52% YoY), while the FY2025 annual figure was $376.3 million, up 168.78% from the prior year.
- Operating Expenses came in at $40.8 million for Q1 2026 at Scilex Holding, down from $115.9 million in the prior quarter.
- The five-year high for Operating Expenses was $197.1 million in Q3 2025, with the low at $15.6 million in Q1 2022.
- Average Operating Expenses over 5 years is $46.9 million, with a median of $32.9 million recorded in 2025.
- The largest YoY upside for Operating Expenses was 11168.15% in 2022 against a maximum downside of 52.42% in 2022.
- Year by year, Operating Expenses stood at $31.7 million in 2022, then grew by 0.45% to $31.8 million in 2023, then surged by 36.09% to $43.3 million in 2024, then jumped by 167.76% to $115.9 million in 2025, then tumbled by 64.81% to $40.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $40.8 million, $115.9 million, and $197.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 6.72 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 9.59 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 11.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -8.41 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.82 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 5.95 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.37 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 5.50 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 40.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.78 Mn |
| Dec 31, 2025 | 115.88 Mn |
| Sep 30, 2025 | 197.07 Mn |
| Jun 30, 2025 | 30.40 Mn |
| Mar 31, 2025 | 32.90 Mn |
| Dec 31, 2024 | 43.28 Mn |
| Sep 30, 2024 | 34.35 Mn |
| Jun 30, 2024 | 31.99 Mn |
| Mar 31, 2024 | 30.36 Mn |
| Dec 31, 2023 | 31.80 Mn |
| Sep 30, 2023 | 48.92 Mn |
| Jun 30, 2023 | 35.40 Mn |
| Mar 31, 2023 | 36.06 Mn |
| Dec 31, 2022 | 31.66 Mn |
| Sep 30, 2022 | 21.99 Mn |
| Jun 30, 2022 | 19.40 Mn |
| Mar 31, 2022 | 15.62 Mn |
| Dec 31, 2021 | 66.53 Mn |
| Sep 30, 2021 | 283,346.00 |
| Jun 30, 2021 | 172,140.00 |